Clinical trial
Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety…
NCT00414687 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00414687 |
|---|---|
| Title | Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension |
| Official title | An Explorative, Open-Label, Multicenter, Randomized, Parallel-Group Comparative Study of Safety, Tolerability, and the Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension Over 2 Years |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hypertension, Pulmonary |
| Intervention type | Drug |
| Interventions | Ventavis (Iloprost, BAYQ6256) |
| Enrollment | 63 |
| Start date | Jul 1, 1998 |
| Completion | May 1, 2001 |
| First posted | Dec 21, 2006 |
| Last update posted | May 15, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: